Dear editor, Focal epithelial hyperplasia (FEH-Heck disease) is a rare disorder caused by specific types of HPV. It mainly involves oral mucosa, and children are affected more frequently. It may persist for years, producing a significant reduction in quality of life. Several treatment modalities such as surgical excision, laser ablation, cryotherapy, electrocauterization, topical, intralesional or systemic interferon, and systemic retinoic acid have been used with variable results and many side effects.
1
In this report, we present a 5-year-old child who has painless lumps in his mouth for one year.
A 5-year-old boy presented with a 1-year history of painless lumps in his mouth. His general health was good. Family history revealed no similar oral lesions. His parents reported that he slept with his mouth open and frequently bit the lesions while eating. Physical examination showed multiple numbers of (approximately 40) mucosa-colored, soft, discrete, flat pap-
Treatment of focal epithelial hyperplasia with topical imiquimod
www.mucosa.org Fokal epitelyal hiperplazinin topikal imikimod ile tedavisi ulonodules, 0.2 to 0.8 cm with lobulated and verrucous surfaces, which were localized on the hard palate, bilateral buccal mucosa, and inner surfaces of upper and lower lips (Fig. 1a ,b,c). The histologic examination was consistent with FEH ( Fig. 2a,b) . All of the lesions were treated with 5% imiquimod cream three nights a week for 16 weeks. Complete blood cell count and biochemical analyzes were normal before and after treatment. No serious side-effects were observed. The patient has remained disease-free during 1-year of follow-up (Fig. 3a,b) .
Focal epithelial hyperplasia may heal within years by itself. The disease is generally of asymptomatic nature, however it may cause discomfort due to dysfunction, traumatization and unpleasant cosmetic appearance caused by the lesions. Moreover, malignant transformation has been reported in long-term FEH cases associated with HPV-24. 2 In our patient, because of the resistance of previous treatments, long-standing and widespread lesions, we have www.mucosa.org considered that the possibility of self-healing was low. The lesions of FEH disappeared after four months of imiquimod treatment. Moreover, the lesions did not recur for a relatively long follow-up period. Therefore, imiquimod may be an effective agent in the treatment of FEH. Topical imiquimod may be a safe, non-invasive, and successful treatment option for pediatric patients with FEH. We suggest that the painless, easy, and self-applicable treatment modalities will help to increase the patient compliance. 
